Volume 28, Number 1—January 2022
Research
Effects of Nonpharmaceutical COVID-19 Interventions on Pediatric Hospitalizations for Other Respiratory Virus Infections, Hong Kong
Susan S. Chiu
, Benjamin J. Cowling, J.S. Malik Peiris, Eunice L.Y. Chan, Wilfred H.S. Wong, and Kwok Piu Lee
, Benjamin J. Cowling, J.S. Malik Peiris, Eunice L.Y. Chan, Wilfred H.S. Wong, and Kwok Piu Lee
Table 1
Pediatric hospitalizations for acute febrile illness or respiratory symptoms caused by viruses other than severe acute respiratory syndrome coronavirus 2 and numbers of infections detected, Pamela Youde Nethersole Eastern Hospital and Queen Mary Hospital, Hong Kong Island, China*
| Month | No. laboratory-confirmed virus infections/no. hospitalizations for acute febrile illness or respiratory symptoms (%) |
||||
|---|---|---|---|---|---|
| 2017, n = 6,010 | 2018, n = 5,445 | 2019, n = 5,44 | 2020, n = 1,525 | 2021, n = 89 | |
| Jan | 349/509 (68.6) | 457/613 (74.6) | 514/646 (79.6) | 291/391 (74.4) | 19/89 (21.3) |
| Feb | 269/424 (63.4) | 377/528 (71.4) | 259/351 (73.8) | 46/136 (33.8) | NA |
| Mar | 332/515 (64.5) | 346/484 (71.5) | 389/503 (77.3) | 31/167 (18.6) | NA |
| Apr | 351/521 (67.4) | 229/375 (61.1) | 327/452 (72.3) | 12/137 (8.8) | NA |
| May | 394/571 (69.0) | 313/451 (69.4) | 339/488 (69.5) | 10/141 (7.1) | NA |
| Jun | 456/608 (75.0) | 271/417 (65.0) | 378/540 (70.0) | 13/88 (14.8) | NA |
| Jul | 557/697 (79.9) | 308/413 (74.6) | 308/471 (65.4) | 14/87 (16.1) | NA |
| Aug | 280/397 (70.5) | 190/332 (57.2) | 195/356 (54.8) | 10/89 (11.2) | NA |
| Sep | 316/461 (68.5) | 259/388 (66.8) | 270/439 (61.5) | 18/83 (21.7) | NA |
| Oct | 293/464 (63.1) | 330/464 (71.1) | 267/433 (61.7) | 13/91 (14.3) | NA |
| Nov | 265/438 (60.5) | 333/462 (72.1) | 219/389 (56.3) | 110/163 (67.5) | NA |
| Dec |
264/405 (65.2) |
396/518 (76.4) |
227/375 (60.5) |
26/85 (30.6) |
NA |
| Median (range), %† | 67.9 (60.1–79.9) | 71.2 (57.2–76.4) | 67.4 (54.8–79.6) | 17.3 (7.1–74.4) | NA |
*Respiratory viruses were influenza A virus, influenza B virus, respiratory syncytial Virus, adenovirus, parainfluenza virus types 1–4, human metapneumovirus, enterovirus/rhinovirus. NA, not applicable. †Kruskal-Wallis test demonstrated significant difference among different years (p<0.001), and Dunn post hoc test indicated a significant difference for only 2020 compared with previous years (p<0.05).
Page created: November 10, 2021
Page updated: December 20, 2021
Page reviewed: December 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.